KLK6 and cancer: Conversely, the possible hypothesis for the decrease of KLK6 in stage III CRC patients might be due to its tumor-suppressive [101,102], and immunologic properties since downregulation of KLK6 was associated with the compromise of immune system via regulation of lymphocytes survival and accelerated cancer progression [103].